Contents
-
news
-
Health
MRNA vaccine targeting pancreatic cancer shows promise in new study of clinical testing
Individual MRNA vaccines have shown positive results in the form of treatment for pancreatic cancer, a phase 1 clinical test was found. According to scientists at the Memorial Slone Catering Cancer Center, half the participants responded to a test vaccine, producing T cells that targeted their tumors, which means that their lifetime could increase by eight years. Less than 13 percent of pancreatic cancer diagnosed is more than five years, which is one of the most deadly types of cancer.
Half of the tests responded to the vaccine, producing T cells that targeted their tumors
Individual MRNA vaccines have shown a promise as a treatment for pancreatic cancer in a phase -1 clinical test, published in the journal Nature. Less than 13 percent of the diagnosis of pancreatic cancer – it is difficult to diagnose quickly because it does not always have clear symptoms, lasting for more than five years, making it one of the most deadly types of cancer.
According to experts, this happens because more than 95 percent of cases are diagnosed when the disease is already advanced.
Pancreatic cancer cells also spread to other parts of the body as compared to other cancers, which only spread when the original tumors grow up. The disease usually does not cause many symptoms until later stages and there is no regular screening for pancreatic cancer such as mammograms or colonoscopy.
Once it is diagnosed, there are very few effective treatment.
“We have made significant progress in improving results in many of other cancers along with new waves of cancer treatment, they have not had much impact on pancreatic cancer,” Dr. Dr. Dr. Olain Center Director for Cancer vaccines. Vinod Balachandran said. In the Memorial Slone Catering Cancer Center, who led the test. “Despite our best current treatments, the survival rate remains about 10 percent.”
He said that strict needs were highlighted for more options.
MRNA technology for other cancer is also being detected
Before the MRNA vaccine was widely used for Covid-19, researchers were already developing technology for cancer treatment. It teaches a person’s immune system to identify and attack the tumor, converting it into a cancer -fighting machine.
MRNA technology is currently being discovered for melanoma and colorectal cancer with other solid tumors.
How does MRNA technology work?
To be effective, MRNA cancer vaccines have to produce a lot of T cells – a type of immune cell that protects the body from invaders. According to experts, these T cells require prolonged lasting and cancer cells to detect and maintain their ability to fight. Although this is a relatively direct achievement when it comes to the virus, teaching a person’s T cells to fight non -cell cells that their body has made themselves more difficult.
For pancreatic cancer, the task is very high.
To teach the body to recognize the tumor for a vaccine, it should be targeted on tumor cells that are unique – meaning that they should not see anywhere else in the body. Since tumors are made from mutation, these mutations are expressed as proteins on the surface of cancer cells, acting as a target.
Pancreatic cancer usually does not have many goals for choosing.
It is popularly believed that lack of mutation – serving as a goal for a MRNA cancer vaccine – will make pancreatic cancer a poor option for therapy. However, the study has proved that this perception may be wrong. The test was a long follow-up for an early 2023 testing-before that the efficacy of vaccines was tested in the heroes of pancreatic cancer.
Phase -1 How was the test conducted?
According to scientists, the new test consisted of 16 patients with pancreatic cancer – who had tumors that could be removed in surgery. Experts stated that this is a relatively rare phenomenon in pancreatic cancer, as only 20 percent of this cancer operates only – the only treatment to prevent it. Chemotherapy, radiation, and immunotherapy shrink or prevent them from growing, but they are not considered a cure.
Balachandran and his team followed patients in the test for four years. The participants had first removed their tumors between 2019 and 2021 for some time. Then, the team used genetic material from each individual tumor, which they hoped to design Perso MRNA vaccines that they would teach the patient’s immune systems to attack their cancer cells.
In addition to the vaccine, all 16 people were also treated with the current standard of care, including surgery, chemotherapy and an immunotherapy drug called ATEZOLISAMAB. Half of the tests responded to the vaccine, producing T cells that targeted their tumors. However, other people did not respond to the vaccine.
Researchers estimated that in those who give a response, vaccines gave their cancer -fighting T cells average of about eight years. They believe that about 20 percent of T cells can survive possible and work for decades.
Now get the latest news with health and braking news and top headlines worldwide.
Pancreatic cancer clinical trial new vaccinePancocyte cancerIt is difficult to diagnose early since any symptomPancreatic cancer cells spread long before the bodyNo regular screening for pancreatic cancerMRNA technology detected for other cancerHow MRNA technology worksMRNA cancer vaccines have to produce tea cellsTumors are made from mutationThe team used genetic material from every tumor
